You can search published articles.

Journal Information

Online ISSN


​Cihat Şen, ​Nicola Volpe

Daniel Rolnik, Mar Gil, Murat Yayla, Oluş Api

Statistics Editor
Resul Arısoy

The effects of gestational diabetes mellitus screening and diagnostic tests on fetal macrosomia

Uğur Keskin, Cihangir Mutlu Ercan, Saadettin Güngör, Kazım Emre Karaşahin, Ali Ergün, Mustafa Öztürk, Özlem Öztürk

Article info

The effects of gestational diabetes mellitus screening and diagnostic tests on fetal macrosomia. Perinatal Journal 2013;21(4):133-137 DOI: 10.2399/prn.13.0213007

Author(s) Information

Uğur Keskin1,
Cihangir Mutlu Ercan1,
Saadettin Güngör1,
Kazım Emre Karaşahin1,
Ali Ergün1,
Mustafa Öztürk2,
Özlem Öztürk3

  1. GATA Kadın Hastalıkları ve Doğum Anabilim Dalı- Ankara TR
  2. Etimesgut Asker Hastanesi Kadın Hastalıkları ve Doğum Servisi- Ankara TR
  3. GATA Tıbbi Biyokimya Anabilim Dalı- Ankara TR
Publication History

Manuscript Received: July 18, 2013

Manuscript Accepted: August 18, 2013

Conflicts of Interest

No conflicts declared.

To assign the detection rate of the clinical gestational diabetes mellitus by using American Diabetes Association criteria, and to compare the results of the 50 g glucose challenge test (GCT) and 100 g oral glucose tolerance test (OGTT) with fetal macrosomia.

The results of 50 g GCT and 100 g OGTT of 690 pregnant were examined for fetal macrosomia. The pregnant divided into three groups. Group 1 included pregnant women with normal glucose challenge test (n=580), Group 2 included pregnant women with abnormal 50 g GCT but normal 100 g OGTT results (n=66), and Group 3 included pregnant women with a diagnosis of gestational diabetes (n=44). The fetal macrosomia rates within groups (?4000 g) and the efficacy of the 50 g GCT and 100 g OGTT to predict fetal macrosomia were evaluated.

The prevalence of the gestational diabetes mellitus was 6.3% (CI 4.7-8.4%). The prevalence of the fetal macrosomia was 4.4% (26/580; CI 3.0-6,4%) in Group 1, 18.1% (12/66; CI 10.7-29,1%) in Group 2, and 34% (15/44; CI 21-48%) in Group 3. For the detection rate of fetal macrosomia, sensitivity and specificity of 50 g GCT and 100 g OGTT were 50%, 55%, and 86% and 65% respectively. Positive predictive values were 24% and 34%. There was significantly positive correlation between 50 g GCT and 100 g OGTT fasting value and birth weight (p). There was no positive correlation between 100 g OGTT (1- hour, 2-hour and 3-hour) and birth weight.

50 g GCT and oral glucose tolerance test are not sensitive tests for prediction of the fetal macrosomia. Even if patients over 140 mg/dL as a result of 50 g GCT screening test are not 100 g OGTT positive, they should be followed up closely in terms of fetal macrosomia as gestational diabetes mellitus patients.

Fetal macrosomia, glucose tolerans test, gestational diabetes mellitus.

Gestational diabetes mellitus (GDM) is defined as the carbohydrate intolerance detected during pregnancy first.[1] Although its prevalence varies by countries, it is generally between 3.1% and 6.8%.[2] Screening and diagnostic tests of gestational diabetes mellitus are performed between 24 and 28 weeks of gestation.[3] Today, there has been still no consensus for the screening and diagnosis tests yet. As in the world, single-phase 75 g OGTT test in addition to 2-phase test approach consisting of 50 g glucose challenge test (GCT) and 100 g oral glucose tolerance test (OGTT) is adopted in Turkey.
The purpose of these screening and diagnostic tests is to establish early diagnosis and to prevent complications that may develop in mother or baby through increases in blood glucose. One of the complications of gestational diabetes is macrosomia.[4] Widely accepted definition of macrosomia is the fetal birth weight over 4000 g.[5] According to the bulletin of American College of Obstetric and Gynecology (ACOG), although considering 4500 g and above as macrosomic is practical, considering as 4000 g and above is more widely accepted in terms of reducing mortality and morbidity.[6,7] There are many risk factors for macrosomic fetus. Gaining too much weight during pregnancy, being obese, postterm pregnancy, and macrosomic fetus history are among these factors. The highest risk factor is to be a diabetic mother. In the studies analyzing fetal macrosomia frequency, fetal macrosomia incidence at GDM is 16-29% while it is 10% in pregnancy not complicated by diabetes.[8] Many risk factors have been presented. Gaining too much weight during pregnancy, being obese, postterm pregnancy, and macrosomic fetus delivery history are among these factors. The highest risk factor is to be a diabetic mother
When the literature is reviewed, it is seen that the pregnant women who have 100 g OGTT results within normal limits despite the high 50 g GCT results are under more risk compared to normal pregnant women in terms of obstetric outcomes.[9,10]
The purpose of our study is to determine GDM prevalence in our own population, to analyze the relationship of fetal macrosomia which one of the GDM complication with the results of 50 g GCT and 100 g OGTT, and to detect cases who have high 50 g GCT results but within normal limits of 100 g OGTT and to evaluate them in terms of fetal macrosomia.

The study performed between September 2009 and August 2010 in Gynecology&Obstetrics Department and Medical Biochemistry Department of GATA Hospital. Results of 999 pregnant women who admitted for 50 g GCT at 24-28 weeks of gestation for routine pregnancy follow-up were evaluated retrospectively. The results of 690 pregnant women who gave birth in our clinic have been reached. Pregnants who were positive for 50 g GCT but no OGTT result, pregnants who had only OGTT results, cases followed up with pre-gestational diabetes diagnosis and multiple pregnancies were excluded from the study. For OGTT, ≥130 mg/dL at 50 g GCT was considered as the limit[11] and 100 g OGTT diagnostic test was applied to patients who were above this limit. Gestational diabetes mellitus diagnosis was established when 2 or more higher values were detected according to ADA criteria (fasting 105 mg/dL, 1-hour 190 mg/dL, 2-hour 165 mg/dL, 3-hour 145 mg/dL).[12] The patients were divided into 3 groups; Group 1 included normal pregnants (n=580; 50 g GCT <130 mg/dL), Group 2 included pregnants who were established GDM diagnosis at the limit (n=66; 50 g GCT ≥130 mg/dL, normal 100 g OGTT results), and Group 1 included pregnants who were established GDM diagnosis (n=44). Those who had birth weight as 4000 g and above were considered as macrosomia. While 13 of the patients in gestational diabetes mellitus group were receiving insulin therapy and following diet, 31 patients only followed diet.
Blood samples collected for glucose challenge test and OGTT were taken into gray-capped (BD Vacutainer Plastic fluoride/oxalate) tubes. Glucose measurement was performed by Olympus AU2700 (Hamburg, Germany) auto-analyzer. Hexokinase method was used as measurement method.
For statistical analyses, Student’s t-test, Pearson correlation analysis and ROC analysis were used on SPSS 15.0 (SPSS Inc., Chicago, IL, USA) program. Results were considered as statistically significant when p value was found to be <0.05.

In 110 (15.9%, CI 13.4-18.8%) of the 690 patients included to the study, 50 g GCT was positive (≥130), 100 g OGTT was used. According to American Diabetes Association (ADA) criteria, 6.3% (44/690; CI 4.7-8.4%) of the patients were established GDM diagnosis.
Mean ages of pregnants were 28.8±4.8 in Group 1, 30.2±4.6 in Group 2, and 32.0±5.2 in Group 3. There was statistically significant difference between Group 1 and Group 3 in terms of age (p<0.001). Mean fetal birth weight was 3422±344 g in Group 1, 3524±455 g in Group 2, and 3380±684 g in Group 3. There was statistically no significant difference between groups in terms of age or fetal birth weights; however, there was statistically significant difference between groups in terms of glycemia values at 50 g GCT (1-hour) and 100 g OGTT (0, 1, 2, and 3-hours) (Table 1).
When all groups were analyzed together, fetal macrosomia rate was found to be 7.6% (53/690; CI 5.9-9.9%). Mean fetal weight of 53 cases who found to have fetal macrosomia was 4189±167 g.
When subgroups were evaluated, fetal macrosomia rate was 4.4% (26/580; CI 3.0-6.4%) in Group 1, 18.1% (12/66; CI 10.7-29.1%) in Group 2 and 34% (15/44; CI 21-48%) in Group 3. Also, when Groups 2 and 3 which have positive 50 g GCT are evaluated together, fetal macrosomia rate was found as 24.5% (27/110; CI 17-33%).
In terms of the relationship of fetal weights of 50 g GCT (+) group (Groups 2 and 3) with GCT and OGTT results, positive correlation was found only between 50 g GCT (1 hour), 100 g OGTT (fasting) and fetal weights (p<0.05); however, there was no correlation between fetal weights and 1-hour, 2-hour and 3-hour of 100 g OGTT (p>0.05).
When groups with and without fetal macrosomia were evaluated separately, significant correlation was found only between birth weights in the group without macrosomia and 2-hour value of 100 g OGTT (p<0.001) while there was no correlation in macrosomic group between 50 g GCT (1-hour) and 100 g OGTT values (Fig. 1).
In Group 2, 50 g GCT result of all macrosomic babies was found to be above 140 mg/dL (Fig. 1). In the ROC analysis of Group 2 with 50 g GCT value at and above 140 mg/dL, macrosomic fetus labor sensitivity was found to be 100% and the specificity was found to be 45.3% (Fig. 2).
For macrosomia of 50 g GCT, the sensitivity was 50%, specificity was 86%, positive predictive value (PPV) was 24%, negative predictive value (NPV) was 95%, and likelihood ratio (LR) was 3.9. For macrosomia of 100 g OGGT according to ADA criteria, sensitivity was found as 55%, specificity as 65%, positive predictive value (PPV) was 34%, negative predictive value (NPV) was 81%, and likelihood ratio (LR) was 1.5.

The prevalence of gestational diabetes mellitus varies between 3.1% and 6.8%.[2] In Turkish population, it was found to be 4.48% according to ADA criteria.[13] In our study, this rate was found as 6.3% (CI 4.7-8.4%).
In our study, the mean age of pregnant women diagnosed with GDM was 32±5 while it was 28.8±4.8 for normal pregnant women. As known, advanced maternal age is a risk factor for GDM; therefore, the findings in our study is consistent with the literature.[14]
Fetal macrosomia is a clinical condition which develops as a result of metabolic events with fetal and maternal traumas associated with mechanical factors, and should be predicted prenatally due to perinatal death; therefore its risk factors and possible complications should be known and intrapartum and postpartum clinical managements should be carried out carefully.
When compared with normoglycemics, macrosomia is three times higher in diabetics and this is associated with various morbidities in the babies of diabetic mothers.[15] In addition to the gestational diabetes, macrosomia history, pre-gestational weight, weight gained during pregnancy, multiparity, male fetus, pregnancies exceeding 40 weeks, and maternal size are the other risk factors for macrosomia. Macrosomia incidence in gestational diabetes is reported as 16-29% in the literature, but this rate is 10% in those without gestational diabetes.[8] In our study, macrosomia incidence was 5.9% in the group without GDM diagnosis (Groups 1 and 2), and it was 34% in the group with GDM diagnosis. Also, macrosomia rate was found to be 24.5% in the group (Groups 2 and 3) which was positive for 50 g GCT. The recent data from Turkey presents macrosomia rate in the general population as 5.15%.[16] In our study, this rate was found as 7.6%.
50 g screening test and 100 g OGTT were compared in the literature when other risk factors are got under control, and it was found that the possibility of delivering macrosomic fetus in cases with high 50 g screening test result but normal 100 g OGTT result was higher than the pregnants with normal 50 g screening test result.[17] In our study, this rate was 4,4% (CI 3.0-6.4%) in Group 1 (26/580) and 18.1% (CI 10.7-29.1%) in Group 2 (12/66).
It was shown in the literature that the most significant risk factor for macrosomia was 140 mg/dL positive GCT.[18] In our study, no macrosomic baby was seen in Group 2 pregnants who were below 140 mg for 50 g GCT. The sensitivity and specificity for delivering macrosomic baby in results at and above 140 mg/dL were found to be 100% and 45.3%, respectively.
In the studies performed in Turkey, a significant relationship was detected between macrosomia and blood glucose value found to be high at OGTT. Also, fasting screening test and 2-hour OGTT blood glucose level were found to be independent risk factors for fetal weight.[19] In our study, where we evaluated the relationship of fetal birth weight with GCT and OGTT results of the group (Groups 2 and 3) which was positive for 50 g GCT, positive correlation was only found between 50 g GCT & OGTT fasting results and birth weights (p<0.05); there was no correlation between OGTT 1-hour, 2-hour, and 3-hour values and birth weights (p>0.05). Groups with and without macrosomia were evaluated separately, birth weights in non-macrosomic group was only correlated with OGTT 2-hour (p<0.001) while there was no significant correlation in 50 g GCT and OGTT values of macrosomic group.
In our study, when threshold value of 50 g GCT was considered as 130 mg/dL, we calculated that sensitivity was 50% (37-63%), specificity was 86% (84-89%), PPV was 24% (17-33%), NPV was 95% (93-96%), and LHR was 3.9 (2.8-5.4) for detecting macrosomia while sensitivity was 55% (37-72%), specificity was 65% (54-74%), PPV was 34% (21-48%), NPV was 81% (70-89%), and LHR was 1.5 (1.0-2.4) for OGTT.

We have concluded that 50 g GCT and 10 g OGTT (fasting, 1-hour, 2-hour, and 3-hour) are not sensitive tests for detecting macrosomic fetus frequency.
1. Metzger BE, Coustan DR. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee. Diabetes Care 1998;21 Suppl 2:B161-7.
2. Dabelea D, Snell-Bergeon JK, Hartsfield CL, Bischoff KJ, Hamman RF, McDuffie RS; Kaiser Permanente of Colorado GDM Screening Program. Increasing prevalence of gestational diabetes mellitus (GDM) over time and by birth cohort: Kaiser Permanente of Colorado GDM Screening Program. Diabetes Care 2005;28:579-84.
3. Benjamin F, Wilson SJ, Deutsch S, Seltzer VL, Droesch K, Droesch J. Effect of advancing pregnancy on the glucose tolerance test and on the 50-g oral glucose load screening test for gestational diabetes. Obstet Gynecol 1986;68:362-5.
4. Brody SC, Harris R, Lohr K. Screening for gestational diabetes: a summary of the evidence for the U.S. Preventive Services Task Force. Obstet Gynecol 2003;101:380-92.
5. Jolly MC, Sebire NJ, Harris JP, Regan L, Robinson S. Risk factors for macrosomia and its clinical consequences: a study of 350,311 pregnancies. Eur J Obstet Gynecol Reprod Biol 2003;111:9-14.
6. ACOG. Intrauterin Growth Restriction. Washington DC-Practice Bulltein. No 12; 2000.
7. ACOG. Fetal Macrosomia. Washington DC-Practice Bulletin No. 22; 2000.
8. Naylor CD, Sermer M, Chen E, Sykora K. Cesarean delivery in relation to birth weight and gestational glucose tolerance: pathophysiology or practice style? Toronto Trihospital Gestational Diabetes Investigators. JAMA 1996;275:1165-70.
9. Dudhbhai M, Lim L, Bombard A, Juliard K, Meenakshi B, Trachelenberg Y, Weiner Z. Characteristics of patients with abnormal glucose challenge test and normal oral glucose tolerance test results: comparison with normal and gestational diabetic patients. Am J Obstet Gynecol 2006;194:e42-5.
10. Ju H, Rumbold AR, Willson KJ, Crowther CA. Borderline gestational diabetes mellitus and pregnancy outcomes. BMC Pregnancy Childbirth 2008;8:31.
11. Öztürk Ö, Serdar MA, Öztürk M, Kurt İ. Calculation of uncertainty for glucose: may it affect the diagnosis of gestational diabetes. Turkish Journal of Biochemistry 2012;37:68-72.
12. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57.
13. Karcaaltincaba D, Kandemir O, Yalvac S, Güvendag-Guven S, Haberal A. Prevalence of gestational diabetes mellitus and gestational impaired glucose tolerance in pregnant women evaluated by National Diabetes Data Group and Carpenter and Coustan criteria. Int J Gynaecol Obstet 2009;106:246-9.
14. Hyer SL, Shehata HA. Gestational diabetes mellitus. Current Obstet Gynaecol 2005;15:368-74.
15. Coustan D. Making the diagnosis of gestational diabetes mellitus. Clinical Obstet Gynecol 2000;43:99-105.
16.  Gül M, Çakar E, Demirci O, Pekin O, Sözen H, Vatansever D, Ertekin AA. Makrozomik gebeliklerin doğum şekilleri ve sonuçları. Zeynep Kamil Bülteni 2012;43:46-52.  
17. Leikin EL, Jenkins JM, Pomerantz GA, Klein L. Abnormal glucose screening test in pregnancy: a risk factor for fetal macrosomia. Obstet Gynecol 1987;69:570-3.
18. Mello G, Parretti E, Mecacci F, Lucchetti R, Lagazio C, Pratesi M, Scarselli G. Risk factors for fetal macrosomia: the importance of a positive oral glucose challenge test. Eur J Endocrinol 1997;137:27-33.
19. Gokcel A, Bagis T, Killicadag EB, Tarim E, Guvener N. Comparison of the criteria forgestational diabetes mellitus by NDDG and Carpenter and Coustan, and the outcomes of pregnancy. J Endocrinol Invest 2002;25:357-61.
Table 1.
Demographic, clinical and laboratory data of pregnants who undergone gestational diabetes mellitus screening at 24-28 weeks of gestation.
Fig 1.
The relationship between birth weight and loading test values.
Fig 2.
The relationship between 50 g glucose screening test and macrosomia - ROC analysis.